An analyst acknowledged Abbott's diagnostics business faces some downside risks, but its medical technology business is buoyed by potential tailwinds.

The Chicago-based company is developing a POC field-effect transistor (FET)-based analyzer that it plans initially to target to the fertility testing space.

Staffing is an issue for the clinical lab industry writ large, but rapid growth in demand and quickly changing technology has made liquid biopsies a particularly tricky area.

Last week, readers were most interested in a story about Tempus' offer to buy cancer diagnostic firm Personalis for $1.5 billion.

NEW YORK – Roche on Friday announced that its molecular test for vaginitis has received 510(k) clearance from the US Food and Drug Administration. The PCR-based Cobas BV/CV test uses ...

NEW YORK – Based on data generated in the National Lung Screening Trial (NLST) cohort, cancer testing firm Mercy BioAnalytics believes its lung cancer early detection assay can identify cancers missed ...

NEW YORK – Quest Diagnostics raised its full-year 2026 revenue and EPS guidance on Thursday as the company saw solid Q2 growth across its business. The firm said it now expects full-year net revenue ...

The IVDR encompasses the firm's ER, PR, and Ki67 testing and completes certification of its overall digital pathology breast suite.

Precision Diabetes said on Thursday that it has acquired the exclusive US commercial rights to Nagase Diagnostics' Lucica Glycated Albumin-L assay for diabetes management. Financial and other terms of ...

The approval allows the company to offer its PD-L1 IHC 22C3 pharmDx Code SK006 CDx for ovarian and other cancers.